Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.
2.

In vitro metabolite identification of ML3403, a 4-pyridinylimidazole-type p38 MAP kinase inhibitor by LC-Qq-TOF-MS and LC-SPE-cryo-NMR/MS.

Kammerer B, Scheible H, Zurek G, Godejohann M, Zeller KP, Gleiter CH, Albrecht W, Laufer S.

Xenobiotica. 2007 Mar;37(3):280-97.

PMID:
17624026
3.

NMR characterization of an S-linked glucuronide metabolite of the potent, novel, nonsteroidal progesterone agonist tanaproget.

Keating KA, McConnell O, Zhang Y, Shen L, Demaio W, Mallis L, Elmarakby S, Chandrasekaran A.

Drug Metab Dispos. 2006 Aug;34(8):1283-7.

4.

Determination of degradation pathways and kinetics of acyl glucuronides by NMR spectroscopy.

Walker GS, Atherton J, Bauman J, Kohl C, Lam W, Reily M, Lou Z, Mutlib A.

Chem Res Toxicol. 2007 Jun;20(6):876-86.

PMID:
17536843
5.

Accelerated metabolite identification by "extraction-NMR".

Gerhard U, Thomas S, Mortishire-Smith R.

J Pharm Biomed Anal. 2003 Jul 14;32(3):531-8.

PMID:
14565558
7.

Selective isolation of in vitro phase II conjugates using a lipophilic anionic exchange solid phase extraction method.

Gagné S, Laterreur J, Mahrouche L, Sørensen D, Gauthier JY, Truong VL, Chauret N, Lévesque JF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 1;863(2):242-8. doi: 10.1016/j.jchromb.2008.01.032.

PMID:
18262477
8.

Characterisation and identification of the human N+-glucuronide metabolite of cediranib.

Lenz EM, Spear M, Drake C, Pollard CR, Ward M, Schulz-Utermoehl T, Harrison M.

J Pharm Biomed Anal. 2010 Nov 2;53(3):526-36. doi: 10.1016/j.jpba.2010.03.023.

PMID:
20409669
10.

Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies.

Mutlib A, Espina R, Atherton J, Wang J, Talaat R, Scatina J, Chandrasekaran A.

Chem Res Toxicol. 2012 Mar 19;25(3):572-83. doi: 10.1021/tx2005629.

PMID:
22292524
11.
12.
13.

Analytical strategies for identifying drug metabolites.

Prakash C, Shaffer CL, Nedderman A.

Mass Spectrom Rev. 2007 May-Jun;26(3):340-69. Review.

PMID:
17405144
14.

HPLC/1H NMR spectroscopic studies of the reactive alpha-1-O-acyl isomer formed during acyl migration of S-naproxen beta-1-O-acyl glucuronide.

Corcoran O, Mortensen RW, Hansen SH, Troke J, Nicholson JK.

Chem Res Toxicol. 2001 Oct;14(10):1363-70.

PMID:
11599927
16.

Development and evaluation of an electrochemical method for studying reactive phase-I metabolites: correlation to in vitro drug metabolism.

Madsen KG, Olsen J, Skonberg C, Hansen SH, Jurva U.

Chem Res Toxicol. 2007 May;20(5):821-31.

PMID:
17447796
17.
18.

750 MHz HPLC-NMR spectroscopic identification of rat microsomal metabolites of phenoxypyridines.

Corcoran O, Spraul M, Hofmann M, Ismail IM, Lindon JC, Nicholson JK.

J Pharm Biomed Anal. 1997 Nov;16(3):481-9.

PMID:
9589407
19.

Metabolite identification via LC-SPE-NMR-MS of the in vitro biooxidation products of a lead mGlu5 allosteric antagonist and impact on the improvement of metabolic stability in the series.

Ceccarelli SM, Schlotterbeck G, Boissin P, Binder M, Buettelmann B, Hanlon S, Jaeschke G, Kolczewski S, Kupfer E, Peters JU, Porter RH, Prinssen EP, Rueher M, Ruf I, Spooren W, Stämpfli A, Vieira E.

ChemMedChem. 2008 Jan;3(1):136-44.

PMID:
17994660
20.

In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.

Lang D, Freudenberger C, Weinz C.

Drug Metab Dispos. 2009 May;37(5):1046-55. doi: 10.1124/dmd.108.025551.

Supplemental Content

Support Center